Nuvectis Pharma (NVCT) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 223.1% versus a loss of 35.5%. Nuvectis Pharma is the larger company by market cap ($657.1 million vs $576.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | PHAT |
|---|---|---|
| Share price | $20.13 | $7.13 |
| Market cap | $657.12M | $576.82M |
| 1-day change | -0.79% | +4.70% |
| YTD return | +166.62% | -57.02% |
| 1-year return | +223.11% | -35.48% |
| 5-year return | — | -78.07% |
| Forward P/E | — | 6.62 |
| EPS (TTM) | $-1.31 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $18.31 |
| 52-week low | $5.55 | $6.52 |
| Distance from 52-week high | -31.24% | -61.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +75.86% | +186.82% |
| Average volume | 215.43K | 1.38M |
| Shares outstanding | 32.64M | 80.90M |
| Employees | 16 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed PHAT by 258.6 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
NVCT vs PHAT FAQ
Which is bigger, Nuvectis Pharma or Phathom Pharmaceuticals?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $657.12M compared with $576.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, NVCT or PHAT?
NVCT returned +223.11% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.